Feed Additives

About Emmyon

Emmyon is a private, preclinical-stage biotech leveraging a unique discovery platform that uses human muscle biopsy mRNA signatures to identify small molecules that reverse muscle atrophy. Its pipeline includes potential therapeutics for conditions like sarcopenia, cancer cachexia, obesity, and type 2 diabetes, as well as commercialized pet health products. Founded in 2020 and based in San Diego, the company is led by a scientifically distinguished team from Mayo Clinic and industry, and is funded in part by NIH SBIR grants.

Therapeutic Areas